Progress Towards Treatment for Drug-Resistant Tuberculosis


Addition of drug counteracted the tolerance of tuberculosis to another anti-tubercular drug.

Researchers were able to create a genetic blueprint of multi-drug resistant and extremely drug resistant Mycobacterium tuberculosis (MTB), which can be used to predict possible treatment targets.

According to a study published in Nature Microbiology, MTB is able to alter gene expression to counteract the immune system and drugs. This allows the drug to mutate and evolve into more resistant strains.

"The incredibly large number of possible drug combinations taken together with the difficulty of growing MTB in the laboratory make discovery of effective combination therapy extremely challenging,” said senior study author Nitin Baliga, PhD. “We hope that our systems-based strategy will accelerate TB drug discovery by helping researchers prioritize combinations that are more likely to be effective.”

In a previous study, researchers created a genome-wide regulatory network model that predicted how MTB senses and responds to factors such as anti-tubercular drugs. In the current study, researchers used this model to see how MTB tolerated the drug bedaquiline, and how pretomanid could counteract resistance to the first drug.

Researchers were able to confirm the mechanism of combined action of the 2 drugs, according to the study.

The findings from this study could potentially accelerate towards novel drug-resistant tuberculosis drugs, the researchers concluded.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Video 5 - "CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC"
Video 8 - "Challenges of Concurrent Administration: RSV and Other Vaccines "
Video 7 - "Raising RSV Awareness Among High-Risk Patient Populations "
© 2024 MJH Life Sciences

All rights reserved.